Purpose of the study
====================

Lersivirine (UK-453,051), a new potent NNRTI, displays novel binding with a unique *in vitro* resistance profile, and shows potential for use against transmitted NNRTI resistant virus and as a candidate for sequential NNRTI therapy. Further *in vitro* analyses have been performed to establish the breadth of activity and identify potential populations that might benefit from lersivirine therapy. Lersivirine activity against various HIV-1 subtypes and viruses with decreased susceptibility to etravirine (ETR) were characterised.

Methods
=======

The PhenoSense™ assay was used to assess the antiviral activity of lersivirine against different HIV-1 subtypes (A, A1, B, BF, C, C/H, D, F, F1, G and H), and the circulating recombinant forms (CRFs) CRF01_AE and CRF02_AG. All were obtained from treatment-naïve patients. Nineteen additional clinical viruses with NNRTI resistance associated mutations (RAMs) were selected based on their reduced susceptibility to ETR.

Summary of results
==================

Lersivirine was active against a panel of 80 clinically- derived viruses representing subtypes A to H, including several CRFs, from a range of geographical origins (geometric mean IC~50~ fold change \[FC\] to reference virus was 0.92). IC~50~ FC were \< 2 for all viruses with the exception of 1 subtype BF and 1 subtype C (geometric mean IC~50~ FC: subtype BF = 0.98, 95% CI 0.64 - 1.49, n=7; subtype C = 1.07, 95% CI 0.88 - 1.30, n=25). Lersivirine retained activity (\< 10 FC IC~50~) for 11 of the 19 viruses with ETR resistance (\> 2.9 FC IC~50~, lower clinical cut-off). Overall, a direct correlation between lersivirine and ETR susceptibility was not found (R^2^ = 0.002). This is consistent with different genotypic resistance profiles. Indeed to date, reduced susceptibility to lersivirine and ETR is associated with the presence of different specific NNRTI RAMs.

Conclusions
===========

Lersivirine showed comparable activity across a range of viruses representing subtypes A to H. The activity of lersivirine against ETR- resistant viruses reflects significant differences in the resistance profiles of lersivirine and ETR consistent with the unique binding of lersivirine in the NNRTI binding pocket. Lersivirine has a distinctive *in vitro* resistance profile and may provide an additional therapy choice for patients with evidence of NNRTI resistance.
